Risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis
Open Access
- 4 March 2026
- journal article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
Abstract
Background Regulatory authorities have raised concerns about potential teratogenic and neurodevelopmental disorders (NDDs) risks associated with paternal valproate use during spermatogenesis, leading to restrictions. We aimed to investigate the association between paternal valproate exposure during spermatogenesis and the risk of NDDs in offspring in Sweden and Norway. Methods We conducted a population-based cohort study of two nationwide cohorts from Sweden and Norway, including all singleton live births (≥22 gestational weeks) from 2007 to 2020. Paternal monotherapy exposure to valproate, lamotrigine or levetiracetam was defined as ≥1 prescription filled for only one of these medications during the 3 months prior to conception. NDDs were identified from health registers from age 1 through 2022. Cox proportional hazards models were used to estimate adjusted HRs (aHRs), accounting for relevant confounders. A random-effects meta-analysis combined results from both countries. Results The Swedish cohort included 1588 children with paternal valproate and 3093 with lamotrigine/levetiracetam monotherapy, while the Norwegian cohort included 463 and 1109, respectively. Compared with paternal lamotrigine/levetiracetam monotherapy, paternal valproate exposure was not associated with increased pooled risk of any NDD (aHR, 1.06; 95% CI 0.81 to 1.22), including autism spectrum disorder (aHR, 1.29; 95% CI 0.89 to 1.85), attention-deficit/hyperactivity disorder (aHR, 0.98; 95% CI 0.76 to 1.25), intellectual disability (aHR, 1.20; 95% CI 0.65 to 2.21; Sweden only) or psychological development disorders (aHR, 1.28; 95% CI 0.84 to 1.97). Findings remained consistent in dose–response analyses and when restricted to fathers with epilepsy. Conclusions In this large Nordic study, paternal valproate use during spermatogenesis was not associated with increased risk of NDDs in offspring, suggesting current regulatory restrictions may warrant re-evaluation.Keywords
Funding Information
- Vetenskapsrådet (DNR 4-2979/2020)
- ALF medicine (n/a)
This publication has 24 references indexed in Scilit:
- Paternal Valproate Use and Neurodevelopmental Disorder and Congenital Malformation Risk in OffspringJAMA Network Open, 2025
- Risk of Neurodevelopmental Disorders and Paternal Use of Valproate During SpermatogenesisJAMA Network Open, 2025
- Valproate Use During Spermatogenesis and Risk to OffspringJAMA Network Open, 2024
- Correlation of drug dose estimated from national prescription registers with mean blood level of antiseizure medication in pregnancyPharmacoepidemiology and Drug Safety, 2024
- Prenatal Exposure to Antiseizure Medications and Risk of Epilepsy in Children of Mothers With EpilepsyJAMA Network Open, 2024
- Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric DisordersJAMA Neurology, 2023
- Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual DisabilityJAMA Neurology, 2022
- Registers of the Swedish total population and their use in medical researchEuropean Journal of Epidemiology, 2016
- The Swedish Multi-generation Register2010
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006